LYMPHOMAS

Hodgkin Lymphoma

A combination of nivolumab plus brentuximab vedotin was highly active in 73% of patients with relapsed/refractory primary mediastinal large B-cell lymphoma, based on results from the phase I/II CheckMate 436 trial, recently announced during the 15th International Conference on Malignant Lymphoma.<br /> &nbsp;

Lymphoma

Diffuse&nbsp;large B-cell lymphoma is the most common adult non-Hodgkin lymphoma, accounting for about a third of&nbsp;all cases.&nbsp;The World Health Organization classification recognizes over&nbsp;15 subtypes of DLBCL, based on the primary tumor site, specific genetic alterations, or association with specific viruses.

David J. Straus, MD, discusses the toxicities associated with the combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with stage III/IV classical Hodgkin lymphoma, according to data from the 3-year update of the ECHELON-1 trial presented at the 2019 ASCO Annual Meeting.

Polatuzumab vedotin in combination with&nbsp;bendamustine and rituximab has been granted an accelerated approval from the FDA for the&nbsp;treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.<br /> &nbsp;

A look back at all the&nbsp;FDA news&nbsp;that happened in the month of&nbsp;May 2019, including several new approvals, orphan drug designations, breakthrough therapy designations, fast track designations, and more.

Copanlisib has been granted with a breakthrough therapy designation from the FDA for the&nbsp;treatment of adult patients with relapsed marginal zone lymphoma who have received at least 2 prior therapies.

Combining&nbsp;lenalidomide with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone did not improve progression-free survival compared with placebo and R-CHOP as a frontline therapy in patients with activated B-cell-type diffuse large B-cell lymphoma, missing the primary endpoint of the phase III ROBUST trial.

Nathan H. Fowler, MD, discusses the latest addition to the treatment landscape for marginal zone lymphoma.

David Miklos, MD, discusses his advice for community oncologists treating patients with diffuse large B-cell lymphoma.

Paul J. Shaughnessy, MD,&nbsp;discusses updates in stem cell mobilization and transplant for DLBCL, including the potential for CAR T-cell therapy to supplant autologous stem cell transplant.